Bruker Unveils Innovations in Microbiology and Infection Diagnostics at ASM Microbe 2026
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
Image: Businesswire
At ASM Microbe 2026, Bruker Corporation showcases its advanced portfolio in microbiology and infection diagnostics, featuring innovations in microbial identification and sepsis diagnostics. Key highlights include the FDA-cleared MALDI Biotyper® CA System and new rapid antimicrobial susceptibility testing workflows aimed at enhancing clinical decision-making.
- 01Bruker's MALDI Biotyper® CA System now supports broader microbial identification with an expanded reference library covering 549 species.
- 02The new rapid antimicrobial susceptibility testing workflow aims to improve diagnostics for bloodstream infections and sepsis.
- 03Bruker introduced multiple new solutions for the U.S. market, including the MBT Easy T® Kit and the MBT HT Library Creator.
- 04The company reported 140 new system placements in the U.S. for 2025, reflecting strong demand for its MALDI Biotyper and IR Biotyper solutions.
- 05Bruker emphasizes the integration of innovations to deliver faster, clinically actionable answers for critical conditions like sepsis.
Advertisement
In-Article Ad
At the ASM Microbe 2026 conference, Bruker Corporation's Microbiology & Infection Diagnostics division presented its expanding portfolio, emphasizing innovations in microbial identification, sepsis diagnostics, and molecular testing. A key highlight is the MALDI Biotyper® CA System, which has received FDA Claims 7 and 8, enhancing microbial identification capabilities in clinical labs. This system includes the MBT Compass® HT CA software and an extensive reference library covering 549 clinically validated microbial species. Bruker is also advancing rapid antimicrobial susceptibility testing (AST) to improve diagnostics for bloodstream infections. New products introduced include the MBT Easy T® Kit and the MBT HT Library Creator, which expands the library to over 5,325 species. The company reported robust growth in its U.S. microbiology business, with 140 new system placements in 2025 and continued demand into 2026. Carla Schneider, Bruker's Director of Commercial Operations, emphasized the importance of integrated innovations for faster clinical decision-making, particularly in critical patient conditions like sepsis.
Advertisement
In-Article Ad
Bruker's advancements in microbiology and infection diagnostics are expected to enhance clinical decision-making and improve patient outcomes in critical care settings.
Advertisement
In-Article Ad
Reader Poll
How important do you think rapid diagnostics are in clinical settings?
Connecting to poll...
More about Bruker Corporation
Read the original article
Visit the source for the complete story.